Ashvattha Therapeutics
Developing a New Class of Intracellular Targeted Therapeutics
San Francisco, United States · Founded 2016 · $238.0M raised
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- avttx.com
- Total Funding
- $238.0M
- Last Round
- $50.0M Extension RoundJan 2025
- Rounds
- 4
About
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company founded by Johns Hopkins scientists that develops hydroxyl dendrimer-based nanomedicines targeting activated microglia and macrophages in diseased tissue. Its lead program, migaldendranib (MGB), is in Phase 1/2 clinical trials for retinal and inflammatory conditions, with the technology enabling precise intracellular drug delivery without affecting healthy cells.
Summary
Ashvattha Therapeutics is a Biotech company based in San Francisco, United States, founded in 2016. It has raised $238.0M in total across 4 rounds, most recently a $50.0M Extension Round round in Jan 2025. Investors include Natural Capital, Tribe Capital and Kennet Partners.
Tech & App Stack
3 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jan 2025
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...